Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Therapeutic effects of lentivirus-mediated shRNA targeting of cyclin D1 in human gastric cancer

Authors: Jin-Hee Seo, Eui-Suk Jeong, Yang-Kyu Choi

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Gastric cancer is the second most common cause of cancer-related death in males and the fourth in females. Traditional treatment has poor prognosis because of recurrence and systemic side effects. Therefore, the development of new therapeutic strategies is an important issue. Lentivirus-mediated shRNA stably inhibits target genes and can efficiently transduce most cells. Since overexpressed cyclin D1 is closely related to human gastric cancer progression, inhibition of cyclin D1 using specific targeting could be an effective treatment method of human gastric cancer.

Methods

The therapeutic effect of lentivirus-mediated shRNA targeting of cyclin D1 (ShCCND1) was analyzed both in vitro and in vivo experiments.

Results

In vitro, NCI-N87 cells with downregulation of cyclin D1 by ShCCND1 showed significant inhibition of cell proliferation, cell motility, and clonogenicity. Downregulation of cyclin D1 in NCI-N87 cells also resulted in significantly increased G1 arrest and apoptosis. In vivo, stable NCI-N87 cells expressing ShCCND1 were engrafted into nude mice. Then, the cancer-growth inhibition effect of lentivirus was confirmed. To assess lentivirus including ShCCND1 as a therapeutic agent, intratumoral injection was conducted. Tumor growth of the lentivirus-treated group was significantly inhibited compared to growth of the control group. These results are in accordance with the in vitro data and lend support to the mitotic figure count and apoptosis analysis of the tumor mass.

Conclusion

The lentivirus-mediated ShCCND1 was constructed, which effectively inhibited growth of NCI-N87-derived cancer both in vitro and in vivo. The efficiency of shRNA knockdown and variation in the degree of inhibition is mediated by different shRNA sequences and cancer cell lines. These experimental results suggest the possibility of developing new gastric cancer therapies using lentivirus-mediated shRNA.
Appendix
Available only for authorised users
Literature
1.
Liu L, Liu N, Xu M, Liu Y, Min J, Pang H, Zhang N, Zhang H, Zhang H: Lentivirus-delivered Kruppel-like factor 8 small interfering RNA inhibits gastric cancer cell growth in vitro and in vivo. Tumour Biol. 2012, 33: 53-61. 10.1007/s13277-011-0245-7.CrossRefPubMed
2.
Lim L, Michael M, Mann GB, Leong T: Adjuvant therapy in gastric cancer. J Clin Oncol. 2005, 23: 6220-6232. 10.1200/JCO.2005.11.593.CrossRefPubMed
3.
Qin XJ, Dai DJ, Gao ZG, Huan JL, Zhu L: Effect of lentivirus-mediated shRNA targeting VEGFR-3 on proliferation, apoptosis and invasion of gastric cancer cells. Int J Mol Med. 2011, 28: 761-768.PubMed
4.
Malumbres M, Barbacid M: Is Cyclin D1-CDK4 kinase a bona fide cancer target?. Cancer Cell. 2006, 9: 2-4. 10.1016/j.ccr.2005.12.026.CrossRefPubMed
5.
Yu Q, Geng Y, Sicinski P: Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001, 411: 1017-1021. 10.1038/35082500.CrossRefPubMed
6.
7.
8.
9.
Xia H, Mao Q, Paulson HL, Davidson BL: siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol. 2002, 20: 1006-1010. 10.1038/nbt739.CrossRefPubMed
10.
Gao S, Dagnaes-Hansen F, Nielsen EJ, Wengel J, Besenbacher F, Howard KA, Kjems J: The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther. 2009, 17: 1225-1233. 10.1038/mt.2009.91.CrossRefPubMedPubMedCentral
11.
Grimm D, Kay MA: RNAi and gene therapy: a mutual attraction. Hematology Am Soc Hematol Educ Program. 2007, 473-481.
12.
Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D: Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol. 1997, 15: 871-875. 10.1038/nbt0997-871.CrossRefPubMed
13.
Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, Piqani B, Eisenhaure TM, Luo B, Grenier JK, Carpenter AE, Foo SY, Stewart SA, Stockwell BR, Hacohen N, Hahn WC, Lander ES, Sabatini DM, Root DE: A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 2006, 124: 1283-1298. 10.1016/j.cell.2006.01.040.CrossRefPubMed
14.
Huszthy PC, Giroglou T, Tsinkalovsky O, Euskirchen P, Skaftnesmo KO, Bjerkvig R, von Laer D, Miletic H: Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy. PLoS One. 2009, 4: e6314-10.1371/journal.pone.0006314.CrossRefPubMedPubMedCentral
15.
Sauter ER, Nesbit M, Litwin S, Klein-Szanto AJ, Cheffetz S, Herlyn M: Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res. 1999, 59: 4876-4881.PubMed
16.
Huang WS, Wang JP, Wang T, Fang JY, Lan P, Ma JP: ShRNA-mediated gene silencing of beta-catenin inhibits growth of human colon cancer cells. World J Gastroenterol. 2007, 13: 6581-6587. 10.3748/wjg.13.6581.CrossRefPubMedPubMedCentral
17.
Liang CC, Park AY, Guan JL: In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007, 2: 329-333. 10.1038/nprot.2007.30.CrossRefPubMed
18.
Tiang JM, Butcher NJ, Minchin RF: Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun. 2010, 393: 95-100. 10.1016/j.bbrc.2010.01.087.CrossRefPubMed
19.
Pearson G, English JM, White MA, Cobb MH: ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation. J Biol Chem. 2001, 276: 7927-7931. 10.1074/jbc.M009764200.CrossRefPubMed
20.
Matsuda Y: Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma. World J Gastroenterol. 2008, 14: 1734-1740. 10.3748/wjg.14.1734.CrossRefPubMedPubMedCentral
21.
Motokura T, Arnold A: Cyclin D and oncogenesis. Curr Opin Genet Dev. 1993, 3: 5-10. 10.1016/S0959-437X(05)80334-X.CrossRefPubMed
22.
Gao P, Zhou GY, Liu Y, Li JS, Zhen JH, Yuan YP: Alteration of cyclin D1 in gastric carcinoma and its clinicopathologic significance. World J Gastroenterol. 2004, 10: 2936-2939.CrossRefPubMedPubMedCentral
23.
Shintani M, Okazaki A, Masuda T, Kawada M, Ishizuka M, Doki Y, Weinstein IB, Imoto M: Overexpression of cyclin DI contributes to malignant properties of esophageal tumor cells by increasing VEGF production and decreasing Fas expression. Anticancer Res. 2002, 22: 639-647.PubMed
24.
Naitoh H, Shibata J, Kawaguchi A, Kodama M, Hattori T: Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol. 1995, 146: 1161-1169.PubMedPubMedCentral
25.
Jiang W, Kahn SM, Zhou P, Zhang YJ, Cacace AM, Infante AS, Doi S, Santella RM, Weinstein IB: Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene. 1993, 8: 3447-3457.PubMed
26.
Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993, 7: 812-821. 10.1101/gad.7.5.812.CrossRefPubMed
27.
Elbashir SM, Harborth J, Weber K, Tuschl T: Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods. 2002, 26: 199-213. 10.1016/S1046-2023(02)00023-3.CrossRefPubMed
28.
Wang S, Liu H, Ren L, Pan Y, Zhang Y: Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interference. Neoplasia. 2008, 10: 399-407.CrossRefPubMedPubMedCentral
29.
Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D: Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998, 72: 9873-9880.PubMedPubMedCentral
30.
Seo JH, Jeong ES, Lee KS, Heo SH, Jeong DG, Choi YK: Lentivirus-mediated shRNA targeting of cyclin D1 enhances the chemosensitivity of human gastric cancer to 5-fluorouracil. Int J Oncol. 2013, 43: 2007-2014.PubMed
31.
Swanton C: Cell-cycle targeted therapies. Lancet Oncol. 2004, 5: 27-36. 10.1016/S1470-2045(03)01321-4.CrossRefPubMed
32.
Tiedemann RE, Schmidt J, Keats JJ, Shi CX, Zhu YX, Palmer SE, Mao X, Schimmer AD, Stewart AK: Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood. 2009, 113: 4027-4037. 10.1182/blood-2008-09-179796.CrossRefPubMedPubMedCentral
33.
Deharvengt SJ, Gunn JR, Pickett SB, Korc M: Intratumoral delivery of shRNA targeting cyclin D1 attenuates pancreatic cancer growth. Cancer Gene Ther. 2010, 17: 325-333. 10.1038/cgt.2009.75.CrossRefPubMed
34.
Sutherland RL, Musgrove EA: Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res. 2002, 4: 14-17.CrossRefPubMed
35.
Mueller MM, Fusenig NE: Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004, 4: 839-849. 10.1038/nrc1477.CrossRefPubMed
36.
Kitadai Y: Cancer-Stromal Cell Interaction and Tumor Angiogenesis in Gastric Cancer. Cancer Microenviron. 2010, 3: 109-116. 10.1007/s12307-009-0032-9.CrossRefPubMed
37.
Hu Z, Sun Y, Garen A: Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci USA. 1999, 96: 8161-8166. 10.1073/pnas.96.14.8161.CrossRefPubMedPubMedCentral
38.
Hu Z, Garen A: Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. Proc Natl Acad Sci USA. 2000, 97: 9221-9225. 10.1073/pnas.97.16.9221.CrossRefPubMedPubMedCentral
39.
Bora RS, Gupta D, Mukkur TK, Saini KS: RNA interference therapeutics for cancer: challenges and opportunities (review). Mol Med Rep. 2012, 6: 9-15.PubMed
40.
Qin B, Cheng K: Silencing of the IKKϵ gene by siRNA inhibits invasiveness and growth of breast cancer cells. Breast Cancer Res. 2010, 12: R74-10.1186/bcr2644.CrossRefPubMedPubMedCentral
41.
Silva J, Chang K, Hannon GJ, Rivas FV: RNA-interference-based functional genomics in mammalian cells: reverse genetics coming of age. Oncogene. 2004, 23: 8401-8409. 10.1038/sj.onc.1208176.CrossRefPubMed
Metadata
Title
Therapeutic effects of lentivirus-mediated shRNA targeting of cyclin D1 in human gastric cancer
Authors
Jin-Hee Seo
Eui-Suk Jeong
Yang-Kyu Choi
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-175

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Study protocol

Standardization of D2 lymphadenectomy and surgical quality control (KLASS-02-QC): a prospective, observational, multicenter study [NCT01283893]

Research article

Special role of Foxp3 for the specifically altered microRNAs in Regulatory T cells of HCC patients

Research article

A DNA repair variant in POLQ (c.-1060A > G) is associated to hereditary breast cancer patients: a case–control study

Research article

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial

Research article

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104

Study protocol

Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits